Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.
More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair.
According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.
There is significant interest in technologies that provide long-range genomic information, but only among a subset of users.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Researchers examined the patient-physician relationship after sharing personal genetic testing results and found that patients may have certain expectations.
A Vanderbilt University survey revealed most clinicians don't need convincing PGx testing is useful, but they don't agree which provider is responsible for the next step.
Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.